background


Product Information:

Birinapant

Birinapant (TL32711) is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM in a cell-free assay, less potent to XIAP. Birinapant helps to induce apoptosis in latent HIV-1-infected cells.

Cat. No.: EX-A258    Purity: >98%
Birinapant
For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
250mg525In-stock
500mg850In-stock
1g1350In-stock
5g4550In-stock
10g6950In-stock
25gget quote


SynonymsTL32711
Synonyms 2TL 32711
CAS No.1260251-31-7
Purity>98%
FormulaC42H56F2N8O6
Mol Weight806.9408
Appearancesolid powder
SolubilitySoluble in DMSO
Shelf Life>2 years if stored properly
StoragePowder -20℃ 2 years; In solvent -20℃ 1 month;
ShippingShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
 
 
Reference:  

[1]. Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71.

[2]. Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94.

[3]. Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24.

[4]. Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79.

CoACoA of Birinapant
Smiles:CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(NC2=C1C=CC(F)=C2)C1=C(C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C2=C(N1)C=C(F)C=C2

KEYWORDS: buy Birinapant | Birinapant supplier | purchase | cost | manufacturer | order | distributor | buy 1260251-31-7 | 1260251-31-7 supplier